Croda International Plc operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Croda International Plc with three other
companies in this sector in the United Kingdom:
Hikma Pharmaceuticals PLC
sales of £1.56 billion [US$2.01 billion]
of which 40%
was Injectable Pharmaceuticals),
(£755.36 million [US$970.90 million]
of which 100%
was Buprenorphine Based Drugs), and
(£620.50 million [US$797.56 million]
of which 39%
was Interventional Medicine).
Croda International Plc reported sales of £1.39 billion (US$1.78 billion)
December of 2018.
a very small
increase of 1.0%
versus 2017, when the company's sales were £1.37 billion.
This was the fourth straight year of sales growth at Croda International Plc.
Sales of Personal Care saw an increase
that was more than double the company's growth rate: sales were up
4.5% in 2018, from
£466.60 million to £487.80 million.
Not all segments of Croda International Plc experienced an increase in sales in 2018:
sales of Industrial Chemicals fell 6.9% to £118.20 million.
Croda International Plc also experienced decreases in sales in
Performance Technologies (down 0.1% to £456.40 million)